loadpatents
Patent applications and USPTO patent grants for Foy; Susan.The latest application filed is for "personalized neoantigen-specific adoptive cell therapies".
Patent | Date |
---|---|
Personalized Neoantigen-specific Adoptive Cell Therapies App 20220010274 - Sennino; Barbara ;   et al. | 2022-01-13 |
Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of an Immune Checkpoint Inhibitor App 20210205429 - Foy; Susan ;   et al. | 2021-07-08 |
Combined Anti Tumor Therapy With A Gitr Agonist And Cpg App 20190263919 - Foy; Susan ;   et al. | 2019-08-29 |
Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor App 20170266270 - FOY; SUSAN ;   et al. | 2017-09-21 |
Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3 App 20170106065 - FOY; SUSAN ;   et al. | 2017-04-20 |
Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor App 20160271239 - FOY; SUSAN ;   et al. | 2016-09-22 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.